Prognostic Factors of Granulosa Cell Tumors: A Retrospective Study in a Tertiary Care Cancer Centre of Eastern India

Kulkarni, Rohini Vinayak; Nayak, Bhagyalaxmi; Parija, Jita; Mohapatra, Janmejaya; Mohapatra, Manoranjan; Padhy, Ashok Kumar

doi:10.1055/s-0041-1740600

Cited by 4 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As chemotherapy has shown only moderate response rates in some trials,23 24 the role of adjuvant chemotherapy in adult granulosa cell tumors is continually questioned and, even in advanced stages,25 no increase in survival could be detected 26. In a recent meta-analysis the response to chemotherapy was evaluated in 58 patients; a complete response was only found in 9% and a partial response in 22% of patients, while 39% had progressive disease 27.…”

Section: Discussionmentioning

confidence: 99%

Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence

Plett

Ricciardi

Vacaru

et al. 2023

Int J Gynecol Cancer

View full text Add to dashboard Cite

ObjectiveAdult granulosa cell tumors represent less than 5% of all ovarian malignancies. The aim of this study was to analyze the clinicopathological parameters and their impact on progression-free and overall survival.MethodsPatients with primary adult granulosa cell tumors treated in three international referral centers between July 1999 and December 2018 were included. The following data were anonymously exported from the prospective database: age at diagnosis, International Federation of Gynecology and Obstetrics (FIGO) stage, adjuvant therapy, surgical procedures, progression-free survival, and overall survival. Descriptive statistical analysis regarding tumor and treatment characteristics was performed. Survival analyses included Kaplan–Meier functions and Cox proportional hazard ratios (HR).ResultsA total of 168 patients with primary adult granulosa cell tumors were included. Median age was 50 years (range 13–82). With regard to stage distribution, 54.2% (n=91) of patients were FIGO stage IA, 1.2% (n=2) were stage IB, 26.8% (n=45) were stage IC, and 17.9% (n=30) were FIGO stage II–IV. 66.7% (n=112) of patients underwent surgical restaging, of whom 17.9% (n=20) were moved to a higher stage. In addition, 36 (21.4%) patients underwent fertility-sparing surgery. After a median follow-up of 61 months (range 0–209), 10.7% of patients (n=18) had recurrent disease and 4.8% (n=8) died of disease. Five-year progression-free survival was 86.1% and estimated overall survival was 95.7%. Five-year progression-free survival was worse for patients with advanced stages (FIGO stage IA/B vs IC: HR 5.09 (95% CI 1.53 to 16.9); FIGO stage IA/B vs II–IV: HR 5.62 (95% CI 1.58 to 19.9)). Nineteen patients receiving adjuvant chemotherapy had lower estimated 5-year progression-free survival compared with patients not receiving chemotherapy (49.7% vs 91.1%, p<0.001; HR 9.15 (95% CI 3.62 to 23.1)).ConclusionThe prognosis of patients with primary adult granulosa cell tumors is mainly determined by FIGO stage. The outcome of patients with FIGO stage IC is comparable to those with advanced stages. Fertility-sparing surgery seems to be a safe procedure in stage IA. Our data do not support the use of adjuvant chemotherapy in early and advanced stages of adult granulosa cell tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence

Plett

Ricciardi

Vacaru

et al. 2023

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

Risk Factors and Clinical Outcomes of Recurrence in Adult Ovarian Granulosa Cell Tumors

Golmohammadi Tavallaee,

Hasanzadeh Mofrad,

Yousefi

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

PurposeGranulosa cell tumors (GCTs) of the ovary are rare but clinically significant malignancies. Despite advances in treatment, recurrence has remained a substantial challenge. This study aimed to identify clinical outcomes and potential prognostic risk factors for recurrence in patients diagnosed with GCTs.MethodsIn a retrospective cohort study, the ovarian cancer database of the gynecological tertiary referral cancer center, Mashhad University of Medical Sciences, Mashhad, Iran, was searched from August 2012 to August 2023 to find GCT cases. Demographic, clinical, pathological, intervention‐related factors, follow‐up, and survival findings were meticulously collected. Data were analyzed using SPSS v 23.ResultsNinety‐two patients with GCTs, including 86 AGCT and 6 JGCT subjects, were identified. Based on further analysis of AGCT patients, most patients were ages under 50 (58.1%), clinically presented pain (32.6%), and abnormal uterine bleeding (27.9%) as the most frequent symptoms. Stages IA (64.0%) and IC (20.9%) were common. Five‐year overall and progression‐free survival were 98.2% and 90.8%, respectively. With a median follow‐up time of 72 (0.0–180) months, disease recurrence was observed in 19 patients (23.9%), and five patients (5.4%) died of the disease. Stage IV was a hazard factor of recurrence (HR = 7.62, 95%CI (1.89–30.63); p = 0.004).ConclusionsThe present study provides valuable insights into the outcomes and potential risk factors for recurrence in ovarian AGCTs. It duplicates the importance of stage in the prognosis of AGCT patients and highlights the safety of fertility‐sparing surgery in stage I and the lack of need to administer chemotherapy in stage IC.

show abstract

The Prognostic Significance of Adjuvant Chemotherapy in Adult Ovarian Granulosa Cell Tumors: A Systematic Review and Meta-analysis

Zhuang,

Yang

2023

Cancer Control

View full text Add to dashboard Cite

Introduction This study aimed to evaluate the oncological and prognostic significance of adjuvant chemotherapy (CT) in patients with adult granulosa cell tumors of the ovary (AOGCT). Methods We searched the Chinese National Knowledge Infrastructure, Clinical Trials, Wanfang Database, Web of Science, Cochrane Library, and MEDLINE electronic databases for articles published up to May 2023. Reference lists of the enrolled studies, Google Scholar, and scientific meeting reports were also manually searched. Results We enrolled 5641 patients with AOGCT from 33 eligible studies, including 1674 (29.7%) and 3967 (70.3%) patients in the CT and non-CT groups, respectively. Based on the cumulative results, adjuvant CT did not affect the risk of recurrence or progression (R/P) (odds ratio [OR]: 1.67, 95% confidence interval [CI]: 1.01–2.78, I2 = 63%, P = .05) and 5-year overall survival (OR: .86, 95% CI: .70–1.04, I2 = 0%, P = .12) of patients with AOGCT. However, adjuvant CT might reduce the 5-year disease-free survival (OR: 2.90, 95% CI: 1.19–7.08, I2 = 55%, P = .02). Sub-group analysis revealed that adjuvant CT did not affect the risk of R/P in patients with early-stage AOGCT (OR: .78, 95% CI: .43–1.43, I2 = 2%, P = .43) and advanced or recurrent AOGCT (OR: .78, 95% CI: .43–1.43, I2 = 2%, P = .43). Conclusion This meta-analysis suggests that patients with AOGCT might not benefit from adjuvant CT, even those with advanced or recurrent disease. The results should be interpreted with caution because of the inherent limitations of retrospective studies.

show abstract

Prognostic Factors of Granulosa Cell Tumors: A Retrospective Study in a Tertiary Care Cancer Centre of Eastern India

Cited by 4 publications

References 25 publications

Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence

Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence

Risk Factors and Clinical Outcomes of Recurrence in Adult Ovarian Granulosa Cell Tumors

The Prognostic Significance of Adjuvant Chemotherapy in Adult Ovarian Granulosa Cell Tumors: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About